Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Tomoko Takimoto-Shimomura"'
Autor:
Yu Inoue, Takahiro Fujino, Shotaro Chinen, Yui Niiyama-Uchibori, Daisuke Ide, Moe Kawata, Keiko Hashimoto, Tomoko Takimoto-Shimomura, Ai Nakayama, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Shigeru Hirano, Junya Kuroda
Publikováno v:
Cureus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad16ebb517d4c8df3c448526390a419a
https://doi.org/10.7759/cureus.38905
https://doi.org/10.7759/cureus.38905
Autor:
Shigeo Horiike, Yayoi Matsumura-Kimoto, Junya Kuroda, Taku Tsukamoto, Saeko Kuwahara-Ota, Tomoko Takimoto-Shimomura, Junko Yamaguchi, Reiko Isa, Yuji Shimura, Daichi Nishiyama, Christian Steinebach, Michael Gütschow, Masafumi Taniwaki, Tsutomu Kobayashi, Yoshimi Mizuno, Yoshiaki Chinen, Yuto Fujibayashi
Publikováno v:
British Journal of Haematology. 191:784-795
An increase in immunosuppressive myeloid-derived suppressor cells (MDSCs) is associated with disease progression and treatment resistance in multiple myeloma (MM). We investigated the mechanisms underlying MDSC induction, and sought to discover a str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaf6cbcf98677ea7ebef3eccc80ccb9a
https://doi.org/10.1111/bjh.16881
https://doi.org/10.1111/bjh.16881
Autor:
Yoshiaki Chinen, Yuji Shimura, Tsutomu Kobayashi, Emiko Sakiyama, Tomoko Takimoto-Shimomura, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Saeko Kuwahara-Ota, Shigeo Horiike, Junya Kuroda
Publikováno v:
Infection and Drug Resistance. 13:1017-1021
Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33321f41a41bb54f3bc9ddb23e2a6140
https://doi.org/10.2147/idr.s249030
https://doi.org/10.2147/idr.s249030
Autor:
Nobuhiko Uoshima, Tomoko Takimoto-Shimomura, Mitsushige Nakao, Hitoji Uchiyama, Shin-ichi Fuchida, Hisao Nagoshi, Hiroto Kaneko, Kazuho Shimura, Shinsuke Mizutani, Yoshiaki Chinen, Mio Sugitani, Yosuke Matsumoto, Toshiki Iwai, Eri Kawata, Yutaka Kobayashi, Mihoko Yoshida, Tsutomu Kobayashi, Yuji Shimura, Chihiro Shimazaki, Muneo Ohshiro, Miki Kiyota, Hikari Nishigaki, Masafumi Taniwaki, Junya Kuroda, Shigeo Horiike
Publikováno v:
International Journal of Hematology. 110:77-85
This multicenter phase II study (UMIN000008145) aims to investigate the efficacy and safety of six cycles of combination therapy (RBD) comprising rituximab, bendamustine, and dexamethasone (DEX) for relapsed or refractory (RR) indolent B-cell non-Hod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd996e9e92278e0d4a6d76a02da44868
https://doi.org/10.1007/s12185-019-02650-w
https://doi.org/10.1007/s12185-019-02650-w
Autor:
Junya Kuroda, Junko Yamaguchi, Daichi Nishiyama, Tsutomu Kobayashi, Shigeo Horiike, Yuji Shimura, Reiko Isa, Tomoko Takimoto-Shimomura, Yoshiaki Chinen, Yuto Fujibayashi, Hiroshi Handa, Taku Tsukamoto, Saeko Kuwahara-Ota, Yayoi Matsumura-Kimoto, Masafumi Taniwaki
Publikováno v:
International journal of hematology. 113(3)
Multiple myeloma (MM) is cytogenetically, genetically and molecularly heterogenous even among subclones in one patient, therefore, it is essential to identify both frequent and patient-specific drivers of molecular abnormality. Following previous mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ae884053f182aa1707e71305cae086
https://pubmed.ncbi.nlm.nih.gov/33095415
https://pubmed.ncbi.nlm.nih.gov/33095415
Autor:
Masakazu Nakano, Yoshiaki Chinen, Shingo Nakahata, Junya Kuroda, Kei Tashiro, Tomoko Takimoto-Shimomura, Toshiya Inaba, Ryuichi Sato, Akinori Kanai, Yoshimi Mizuno, Yuka Kawaji, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Saeko Kuwahara-Ota, Saori Maegawa-Matsui, Kazuhiro Morishita, Masafumi Taniwaki
Background Since bromodomain-containing protein 4 (BRD4) facilitates the transcription of genes important for neoplastic cells in a cancer-type specific manner, BRD4-regulated molecules may also include therapeutic targets for mantle cell lymphoma (M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7569396823cf2bc0f2a2d732c13253b
https://europepmc.org/articles/PMC6937128/
https://europepmc.org/articles/PMC6937128/
Autor:
Yuji Shimura, Kazuna Tanba, Yayoi Matsumura-Kimoto, Yoshiaki Chinen, Yoshimi Mizuno, Tsutomu Kobayashi, Taku Tsukamoto, Saeko Kuwahara-Ota, Shigeo Horiike, Junya Kuroda, Shinsuke Mizutani, Tomoko Takimoto-Shimomura
Publikováno v:
Infection and Drug Resistance
Primary infection with human herpesvirus-6 (HHV-6) commonly occurs at an early age in children, most often at 3 years of age, and is associated with childhood diseases, such as exanthema subitum, hepatitis, febrile convulsions, or encephalitis. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe37ce2a16d7bbb825f690ea0cdae476
https://doi.org/10.2147/idr.s163686
https://doi.org/10.2147/idr.s163686
Autor:
Taku Tsukamoto, Kenji Nagata, Chie Sotozono, Junya Kuroda, Yuji Shimura, Shigeo Horiike, Tohru Inaba, Tomoko Takimoto-Shimomura, Yoshiaki Chinen, Tsutomu Kobayashi
Publikováno v:
Annals of Hematology. 98:2617-2619
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::692ea584613a057ad56d1d07a0e06f63
https://doi.org/10.1007/s00277-019-03807-7
https://doi.org/10.1007/s00277-019-03807-7
Autor:
Masafumi Taniwaki, Nobuhiko Uoshima, Nana Sasaki, Tsutomu Kobayashi, Tomoko Takimoto-Shimomura, Takahiro Fujino, Reiko Isa, Sonoko Nakano-Akamatsu, Kazuho Shimura, Taku Tsukamoto, Ryoichi Takahashi, Eri Kawata, Yuri Kamitsuji, Yoshiaki Chinen, Shinsuke Mizutani, Hiroto Kaneko, Junya Kuroda, Hitoji Uchiyama, Yuji Shimura, Muneo Ohshiro, Yuka Kawaji
Publikováno v:
Annals of hematology. 99(1)
The combinations of melphalan, bortezomib, and prednisolone (VMP) and of lenalidomide and dexamethasone (Rd) are standard treatment strategies for transplant-ineligible newly diagnosed multiple myeloma (NDMM). To make the most of these two strategies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06091c2d5cca6ab411e6fd6a5fc1c998
https://pubmed.ncbi.nlm.nih.gov/31768675
https://pubmed.ncbi.nlm.nih.gov/31768675
Autor:
Yuji Shimura, Masafumi Taniwaki, Tsutomu Kobayashi, Saori Maegawa-Matsui, Shigeo Horiike, Tomoko Takimoto-Shimomura, Yoshimi Mizuno, Kazuna Tanba, Yoshiaki Chinen, Junya Kuroda, Yuto Fujibayashi, Taku Tsukamoto, Saeko Kuwahara-Ota, Yayoi Matsumura-Kimoto
Publikováno v:
Experimental Hematology. 84:45-53.e1
Cyclin D1 (CCND1) overexpression is an early and unifying oncogenic event in mantle cell lymphoma (MCL) and multiple myeloma (MM) with chromosome 11q13 abnormalities. Herein, we report newly discovered transcript variants of the CCND1 gene in MCL and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58190432547699dd2f8fdaf26faf6438
https://doi.org/10.1016/j.exphem.2020.02.004
https://doi.org/10.1016/j.exphem.2020.02.004